Attached files
file | filename |
---|---|
8-K - WINDTREE THERAPEUTICS INC /DE/ | v195133_8k.htm |
Discovery
Labs Realigns Executive Management
Warrington, PA — August 24, 2010 —
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announces a realignment
of the Company’s executive management by appointing Dr. Thomas F. Miller as
Chief Operating Officer, Mr. Charles F. Katzer as Chief Technical Officer, and
Mr. John G. Cooper as President and Chief Financial Officer. These positions
will report directly to Mr. W. Thomas Amick, Chairman of the Board and Interim
Chief Executive Officer of Discovery Labs.
Mr. Amick commented, “We are realigning
the leadership and technical talents of our executive team to strengthen our
Company and better position us to execute our business plans
successfully. Additionally, we intend to recruit for the Chief
Executive Officer role with the goal of filling this key leadership position in
2011.”
Thomas F. Miller, PhD., MBA, has been
appointed Chief Operating Officer and will have responsibility for product
development (including preclinical and clinical operations), regulatory affairs,
and corporate and commercial development for the Company. Dr.
Miller’s relevant biopharmaceutical experience includes product development and
commercial operations with Pfizer, Novartis, BASF Pharmaceuticals, Pharmacia,
and Johnson & Johnson. Dr. Miller has significant related
experience in the development of new therapies for neonatal critical care and
with commercial strategy development for new synthetic alternatives to animal-derived
medications. Additionally, he has developed a long-standing and well
established relationship base with key neonatology and pulmonology academic
thought leaders, including many currently collaborating with the Company. Dr.
Miller initially joined Discovery Labs in 2004 and has most recently served as
Senior Vice President, Commercial and Corporate Development.
Charles F. Katzer has been appointed
Chief Technical Officer and will have responsibility for manufacturing
operations, aerosol device development, formulations development, quality
control and assurance, and analytical services. Mr. Katzer has over
35 years of related experience in drug manufacturing and supply, device
development, and quality operations within the biopharmaceutical industry
including Biological Specialties, MedImmune, U.S. Bioscience, Rhone-Poulenc
Rorer and Baxter, and has successfully developed and manufactured small molecule
and complex biotechnology drug products. Mr. Katzer has been with Discovery Labs
since 2006, most recently serving as Senior Vice President, Manufacturing
Operations.
John G. Cooper has been appointed
President and Chief Financial Officer and will be responsible for the strategic and organizational
development of the Company
while retaining overall
responsibility for the
Company’s financial operations. Mr. Cooper has over 25 years of
experience in the life
sciences industry including C.R. Bard, ENI Diagnostics, DNX Corporation, and
Chrysalis Corporation, and has significant experience in managing emerging growth companies, public and
private equity financings, investor relations, strategic alliances, and mergers
and acquisitions. Mr. Cooper most recently served as the Company’s Executive
Vice President and has been Chief Financial Officer since joining Discovery Labs
in 2001.
About
Discovery Labs
Discovery
Laboratories, Inc. is a biotechnology company developing KL4 surfactant
therapies for respiratory diseases. Surfactants are produced naturally in
the lungs and are essential for breathing. Discovery Labs’ novel
proprietary KL4 surfactant
technology produces a synthetic, peptide-containing surfactant that is
structurally similar to pulmonary surfactant and is being developed in liquid,
aerosol or lyophilized formulations. In addition, Discovery Labs’
proprietary capillary aerosolization technology produces a dense aerosol, with a
defined particle size that is capable of potentially delivering aerosolized
KL4
surfactant to the deep lung without the complications currently associated with
liquid surfactant administration. Discovery Labs believes that its
proprietary technology platform makes it possible, for the first time, to
develop a significant pipeline of surfactant products to address a variety of
respiratory diseases for which there frequently are few or no approved
therapies. For more information, please visit our website at www.Discoverylabs.com.
Contact
Information:
John G.
Cooper, President and Chief Financial Officer
215-488-9490